Main outcomes reported in the included studies
| Author | Year | Open (n) | MIS (n) | Relapse open | Relapse MIS | Relapse rate open | Relapse rate MIS | Definition OS/PFS | DFS open | D DFS MIS | Death open | Death MIS | OS open | OS MIS |
| Chen C et al 22 | 2020 | 926 | 926 | 37 | 44 | 4.0% | 4.8% | Not provided | 5 year 94.9% | 5 year 92.6% | 22 | 18 | 5 year 96.6% | 5 year 96.3% |
| Chen X et al 21 | 2020 | 196 | 129 | 5 | 11 | 2.6% | 8.5% | Not provided | 5 year 97.7% | 5 year 90.4% | 3 | 4 | 5 year 99.4% | 5 year 96.9% |
| Chiva et al 20 | 2020 | 160 | 128 | 15 | 17 | 9.4% | 13.3% | From surgery | HR 1.63 (95% CI 0.79 to 3.40) favor open | 5 | 8 | HR 2.77 (0.91 to 8.47) favor open | ||
| Hu et al 16 | 2020 | 147 | 147 | 9 | 5 | 6.1% | 3.4% | From surgery | 5 year 94.3% | 5 year 97.3% | 2 | 2 | 5 year 97.6% | 5 year 99.3% |
| Kim et al 15 | 2019 | 122 | 122 | 11 | 10 | 9.0% | 8.2% | From diagnosis | 3 year 93.1% | 3 year 90% | 9 | 2 | 5 year 96.4% | 5 year 98.6% |
| Nam et al 13 | 2012 | 173 | 162 | 5 | 8 | 2.9% | 4.9% | From surgery | 5 year 97.4% | 5 year 94.2% | 3 | 5 | n/a | n/a |
| Paik et al 12 | 2019 | 186 | 62 | 1 | 6 | 0.5% | 9.7% | From surgery | HR 12.987 (1.45 to 116.24) favor open | 0 | 1 | n/a | n/a | |
| Rodriguez et al 24 | 2021 | 492 | 486 | n/a | n/a | n/a | n/a | From surgery | HR 1.44 (0.85 to 2.45) | n/a | n/a | HR 2.44 (1.05 to 5.67) | ||
| Uppal et al 10 | 2020 | 82 | 182 | 2 | 16 | 2.4% | 8.8% | From surgery | aHR:6.31 (1.24 to 31.9) favor open | n/a | n/a | n/a | n/a | |
| Yang et al 11 | 2020 | 57 | 50 | n/a | n/a | n/a | n/a | From surgery | HR 1.695 (0.29 to 9.77) | n/a | n/a | HR 2.69 (0.48 to 15.07) | ||
aHR, adjusted hazard ratio; DFS, disease-free survival; MIS, minimally invasive surgery; n/a, not available; OS, overall survival; PFS, progression-free survival.